Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30232435 | 1.00 | CHRNB2 (0.49) | CHRNB2CHRNA4HRH4 | |
| SCHEMBL30232647 | 0.87 | CHRNB2 (0.44) | CHRNB2CHRNA4HRH4 | |
| SCHEMBL27404860 | 0.83 | CHRNB2 (0.47) | CHRNB2CHRNA4 | |
| SCHEMBL31485105 | 0.83 | CHRNB2 (0.47) | CHRNB2CHRNA4HRH4 | |
| SCHEMBL15790545 | 0.75 | CHRNB2 (0.68) | CHRNB2CHRNA4 | |
| SCHEMBL3711991 | 0.75 | CHRNB2 (0.68) | CHRNB2CHRNA4 | |
| SCHEMBL4922447 | 0.75 | CHRNB2 (0.58) | CHRNB2CHRNA4 | |
| Bromide SCHEMBL15775912 | 0.74 | CHRNB2 (0.66) | CHRNB2CHRNA4 | |
| Bromide SCHEMBL27157764 | 0.74 | CHRNB2 (0.66) | CHRNB2CHRNA4 | |
| SCHEMBL5638049 | 0.74 | PKM (0.50) | CHRNB2CHRNA4HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299348-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. | 2024-09-12 | — | — | US | disclosed |
| WO-2022150461-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022150461-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299348-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | TRPM5, TRPM6, TRPM2 | CHRNB2 992/4885CHRNA4 1323/4885HRH4 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.